How to Sell a Hospice Agency in 2026: The Complete Guide

Hospice is the most valuable segment in home-based care M&A — and the most technical to sell. The same factors that produce 6–12× EBITDA multiples (licensure scarcity, regulatory moats, recurring Medicare reimbursement) also produce the industry’s most demanding diligence process. This guide walks through the entire sale, from what actually drives hospice value to the day your CHOW clears.

Why Hospice Multiples Lead the Industry

Three structural forces keep hospice at the top of the multiples table:

1. Demographics: 11,000 Americans turn 65 every day, and hospice utilization among decedents keeps climbing.
2. Constrained supply: CON states and periodic CMS enrollment moratoria make licenses scarce. In several states, the fastest legal route to market entry is buying an existing provider — which puts a floor under license value itself.
3. Payer simplicity: ~90%+ Medicare revenue at per-diem rates means predictable, contract-free cash flow — the profile institutional buyers pay up for.

The Five Hospice-Specific Value Drivers

1. Average Daily Census (ADC) — scale and trajectory

ADC is hospice’s headline metric. Rough 2026 market brackets:

ADC	Buyer Universe	Typical Multiple Range
Under 30	Local/regional tuck-ins	4–6×
30–75	Regional platforms, some nationals	6–8×
75–150	Full institutional universe	7–10×
150+	Platform-grade asset	9–12×

Trajectory matters as much as level: a 60-ADC hospice growing 20% annually can out-price a flat 90-ADC agency.

2. Cap cushion

The Medicare aggregate cap is hospice’s unique liability. Buyers will recompute your cap position for all open cap years — and they hire specialists to do it. An agency running close to its cap (long-stay-heavy census) carries contingent liability that comes straight off the price or lands in escrow. Know your cushion before your buyer does.

3. Referral source diversity

One hospital system or one SNF chain producing 50%+ of admissions is the hospice version of client concentration. Buyers model what happens if that relationship walks. Under 25% from any single source is the comfort zone.

4. Survey, audit, and compliance history

Recent state survey results, any condition-level deficiencies, TPE/UPIC/ADR activity, and OIG exclusion screening on staff. A clean three-year compliance file doesn’t just protect value — it accelerates timeline, because buyers extend less diligence to clean assets.

5. Length-of-stay mix

Very short median LOS (heavy late referrals) hurts economics; very long LOS raises cap and audit risk. Buyers want the balanced middle with documented eligibility on long-stay patients — your live discharge rate and recert documentation will be read closely.

The Sale Process, Stage by Stage

Months 1–2: Preparation

• Normalize EBITDA (owner comp, one-time costs, related-party rent — add-backs guide)
• Commission an independent cap analysis for all open years
• Pull three years of survey results, audit correspondence, and PEPPER reports
• Assemble the data room and CIM

Months 2–4: Market and Negotiate

A confidential, competitive process — never a public listing — brings qualified hospice buyers to the table under NDA. Expect IOIs, management presentations with 2–4 finalists, then LOIs. Structure points to negotiate hard in hospice specifically: cap-liability escrow sizing, treatment of open audit years, and clinical-leadership retention packages (your medical director and DON matter to buyers).

Months 4–6: Diligence and Documentation

Hospice diligence adds to the standard checklist: clinical chart audits on eligibility documentation, cap recomputation, billing pattern analysis (GIP utilization, live discharge rates), and licensure/CHOW planning.

Months 6–12: Regulatory Approvals and Close

The CMS CHOW process plus state license transfer set the closing timeline. Deal structures respond to this: some close into escrow pending CHOW acceptance; asset deals versus stock deals have very different regulatory paths in hospice — stock deals often preserve the provider agreement and move faster, which is why hospice trades as equity more often than home care.

The Three Deal Killers to Neutralize Early

1. Cap surprises. Recompute before market. Every time.
2. Eligibility documentation gaps on long-stay patients — a chart remediation sprint before diligence is cheap insurance.
3. Key-person risk in clinical leadership. Buyers assume your census follows your people; retention agreements (funded by the buyer, negotiated by you) close the gap.

Bottom Line

Hospice sellers in 2026 have demographics, scarcity, and an aggressive buyer universe on their side. What they don’t have is room for sloppiness — cap liability, eligibility documentation, and CHOW mechanics punish unprepared sellers harder than in any other segment. Preparation plus competition is the entire formula.

Want a confidential read on your hospice’s value — including a cap-cushion sanity check? Book a free 20-minute valuation call. Strictly confidential, no obligation.